Treatment variation in stent choice in patients with stable or unstable coronary artery disease.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMID 26762359)

Published in Neth Heart J on February 01, 2016

Authors

L T Burgers1, E A McClellan2, I E Hoefer3, G Pasterkamp3, J W Jukema4, S Horsman5, N H J Pijls6, J Waltenberger7,8, M A Hillaert9, A C Stubbs5, J L Severens10, W K Redekop10

Author Affiliations

1: Institute of Health Policy & Management, and Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands. ltburgers@gmail.com.
2: Department of Mathematical and Computer Sciences, Metropolitan State University of Denver, Colorado, USA.
3: Laboratory of Experimental Cardiology, UMC Utrecht, Utrecht, The Netherlands.
4: Department of Cardiology, Leiden UMC, Leiden, The Netherlands.
5: Department of Bioinformatics, Erasmus Medical Center, Rotterdam, The Netherlands.
6: Department of Cardiology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
7: Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.
8: Department of Cardiovascular Medicine, University of Münster, Münster, Germany.
9: Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
10: Institute of Health Policy & Management, and Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

Articles cited by this

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J (2011) 13.10

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J (2014) 9.73

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Economic evaluation of sirolimus-eluting stents. CMAJ (2005) 1.32

Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess (2004) 1.18

Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess (2007) 1.10

Determinants of variations in coronary revascularization practices. CMAJ (2011) 1.08

Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med (2009) 1.07

Ultra-thin strut cobalt chromium bare metal stent usage in a complex real-world setting. (SOLSTICE registry). Neth Heart J (2015) 0.99

Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth Heart J (2015) 0.98

Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol (2005) 0.92

Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scand Cardiovasc J (2006) 0.90

Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. Clin Res Cardiol (2013) 0.88

Economic evaluation of drug-eluting stents: a systematic literature review and model-based cost-utility analysis. Int J Technol Assess Health Care (2007) 0.88

Variations in the use of an innovative technology by payer: the case of drug-eluting stents. Med Care (2012) 0.88

Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data. Value Health (2011) 0.87

Cost effectiveness of drug-eluting stents in Belgian practice: healthcare payer perspective. Pharmacoeconomics (2009) 0.86

Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. Int J Technol Assess Health Care (2009) 0.86

Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. J Public Health (Oxf) (2008) 0.83

Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. EuroIntervention (2010) 0.82

Economic analysis of the use of drug-eluting stents from the perspective of Belgian health care. Acta Cardiol (2007) 0.81

Stent platforms anno 2015: is there still a place for bare metal stents at the front line? Neth Heart J (2015) 0.79